Picard Medical, Inc. (PMI) - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K covers events occurring on May 5, 2026, and May 8, 2026. Picard Medical, Inc., a Delaware corporation listed on the NYSE American, reported the closing of a registered public offering and the receipt of a delisting notice from the exchange due to non-compliance with stockholders' equity standards.
Key Financial Metrics and Capital Structure
- Gross Proceeds: Approximately $5.0 million from the sale of 16,666,667 Offered Shares (or Pre-Funded Warrants) and accompanying warrants.
- Offering Price: $0.30 per share for Offered Shares with warrants; $0.2999 for Pre-Funded Warrants with warrants.
- Transaction Costs: 7.0% cash fee to the placement agent and 1.0% management fee to a financial advisor.
- Stockholders' Equity: Approximately $3.8 million as of December 31, 2025.
- Profitability: The company reported losses from continuing operations and/or net losses in three of its four most recent fiscal years.
- Use of Proceeds: Working capital, general corporate purposes, and debt repayment.
Material Changes and Events
- Capital Raise: The company completed a registered public offering on May 6, 2026, issuing common stock, pre-funded warrants, and two series of warrants (Series A and Series B).
- Listing Status: On May 8, 2026, the NYSE American notified the company of non-compliance with Section 1003(a)(ii) of the Company Guide due to stockholders' equity falling below the $4.0 million threshold.
- Trading Designation: The company's stock will trade with a ".BC" suffix to indicate "below compliance" status.
Outlook, Risks, and Management Commentary
- Compliance Plan: The company must submit a plan to the NYSE American by June 7, 2026, to regain compliance by November 8, 2027.
- Delisting Risk: Failure to submit an acceptable plan or meet compliance standards by the November 2027 deadline will result in delisting procedures.
- Lock-Up Agreements: Directors, officers, and 10% stockholders are subject to a 30-day lock-up. The company is restricted from issuing new shares for 60 days and entering variable rate transactions for 90 days post-closing.
- Warrant Terms: Common Warrants are exercisable at $0.35 per share. Series A Warrants expire in five years; Series B Warrants expire in 24 months.
Investor Verification Checklist
- Verify the exact amount of net proceeds after deducting the 8% total fees and offering expenses.
- Confirm the specific debt obligations targeted for repayment with the new capital.
- Review the detailed compliance plan to be filed by June 7, 2026, to assess the feasibility of regaining listing standards.
- Monitor the ".BC" trading designation and potential impact on liquidity and market perception.
- Check the full text of the Purchase Agreement and Placement Agency Agreement (Exhibits 1.1 and 10.1) for additional covenants or conditions.